Results 251 to 260 of about 160,542 (279)

Adverse drug reaction assessment of pembrolizumab and nivolumab in esophageal cancer treatment based on the US FAERS database. [PDF]

Front Immunol
Chen J, Xu Q, Ying Y, Yu J, Liu Y, Zhao F, Shu Q.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Pembrolizumab

Reactions Weekly, 2023
  +8 more sources

Pembrolizumab

Reactions Weekly
  +12 more sources

Pembrolizumab

Reactions Weekly, 2021
  +8 more sources

Pembrolizumab

Reactions Weekly, 2022
  +7 more sources

Pembrolizumab

Reactions Weekly, 2018
  +4 more sources

Tumor dynamics in patients with solid tumors treated with pembrolizumab beyond disease progression

Cancer Cell, 2023
Alexandra Snyder, Jedd D Wolchok, Antoni Ribas   +2 more
exaly  

Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189

Annals of Oncology, 2021
Delvys Rodríguez-Abreu, S F Powell, S Gadgeel   +2 more
exaly  

Pembrolizumab

Reactions Weekly, 2019
  +4 more sources

Pembrolizumab

Reactions Weekly, 2016
  +4 more sources